SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA
Nephrology Dialysis Transplantation · 31.10.2023 · 38 (11) · 2444-2455
DOI: 10.1093/ndt/gfad112 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 25.05.2023. Verfasst von Patrick B Mark und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic, Cardiovascular Diseases, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medical Research Council, FEDER, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Chronic kidney disease (CKD) is a major public health issue affecting an estimated 850 million people globally. The leading causes of CKD is diabetes and hypertension, which together account for >50% of patients with end-stage kidney disease. Progressive CKD leads to the requirement for kidney replacement therapy with transplantation or dialysis. In addition, CKD, is a risk factor for premature cardiovascular disease, particularly from structural heart disease and heart failure (HF). Until 2015, the mainstay of treatment to slow progression of both diabetic and many non-diabetic kidney diseases was blood pressure control and renin-angiotensin system inhibition; however, neither angiotensin-converting enzyme inhibitors (ACEIs) nor angiotensin receptor blockers (ARBs) reduced cardiovascular events and mortality in major trials in CKD. The emergence of cardiovascular and renal benefits observed with sodium-glucose cotransporter-2 inhibitors (SGLT2i) from clinical trials of their use as anti-hyperglycaemic agents has led to a revolution in cardiorenal protection for patients with diabetes. Subsequent clinical trials, notably DAPA-HF, EMPEROR, CREDENCE, DAPA-CKD and EMPA-KIDNEY have demonstrated their benefits in reducing risk of HF and progression to kidney failure in patients with HF and/or CKD. The cardiorenal benefits—on a relative scale—appear similar in patients with or without diabetes. Specialty societies’ guidelines are continually adapting as trial data emerges to support increasingly wide use of SGLT2i. This consensus paper from EURECA-m and ERBP highlights the latest evidence and summarizes the guidelines for use of SGLT2i for cardiorenal protection focusing on benefits observed relevant to people with CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
- Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Faculty of Medicine, University of Maribor, Taborska 8, Maribor, Slovenia.
- Renal Unit, University Hospitals Birmingham and Institute of Cardiovascular Science, University of Birmingham, Birmingham, UK.
- Department of Nephrology, University Hospital of Ioannina, Ioannina, Greece.
- Division of Nephrology and Hypertension, IIS-Fundación Jiménez Díaz-Universidad Autónoma Madrid. Spain, Spain.
Förderung
- Medical Research Council
- FEDER
- Instituto de Salud Carlos III
- European Union
Zitieren
APA
Mark, P. B., Sarafidis, P., Ekart, R., Ferro, C. J., Balafa, O., Fernandez-Fernandez, B., Herrington, W. G., Rossignol, P., Del Vecchio, L., Valdivielso, J. M., Mallamaci, F., Ortiz, A., Nistor, I., & Cozzolino, M. (2023). SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA. Nephrology Dialysis Transplantation, 38(11), 2444-2455. https://doi.org/10.1093/ndt/gfad112
Vancouver
Mark PB, Sarafidis P, Ekart R, Ferro CJ, Balafa O, Fernandez-Fernandez B, et al. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA. Nephrology Dialysis Transplantation. 2023;38(11):2444-2455. doi:10.1093/ndt/gfad112
BibTeX
@article{Mark2023,
author = {Mark, Patrick B and Sarafidis, Pantelis and Ekart, Robert and Ferro, Charles J and Balafa, Olga and Fernandez-Fernandez, Beatriz and Herrington, William G and Rossignol, Patrick and Del Vecchio, Lucia and Valdivielso, Jose M and Mallamaci, Francesca and Ortiz, Alberto and Nistor, Ionut and Cozzolino, Mario},
title = {SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA},
journal = {Nephrology Dialysis Transplantation},
year = {2023},
volume = {38},
number = {11},
pages = {2444--2455},
doi = {10.1093/ndt/gfad112}
}
EUVIMED